Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
- Reuters
The total cash amount that Purchaser will pay pursuant to the terms of the Offer and the Merger Agreement is $2.13 per share.
JMP Securities analyst Roy Buchanan downgrades Pardes Biosciences (NASDAQ:PRDS) from Market Outperform to Market Perform.
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Al...
Pardes Biosciences Inc (NASDAQ: PRDS) shares are trading higher Monday after MediPacific agreed to acquire the company.
Pardes Biosciences (NASDAQ:PRDS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(...
